The application of monoclonal antibodies that targeted either the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) pathway has shown superior clinical outcomes in HCC [2]. Here, PDCD1 is linked to hepatocellular carcinoma.